Search the Newsreel

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested Pays Annually.

If you're not aware of them, there's a group of stocks known as Dividend Kings. This select group of companies have all increased their dividends annually for at least 50 consecutive years. A few of these Dividend Kings have done much better. Drug and …

Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid …

This 5.3% Monthly Payer Only Buys Stocks That Raised Dividends 10 Straight Years, It’s Up 18.5% in 2026

Quick Read PEY requires 10 straight years of dividend growth before yield ranking, and it delivered roughly 25% in 2026, which is nearly double the S&P 500's gain. Altria has raised its dividend 60 consecutive times over 56 years, while Johnson & Johnson just …

Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?

Quick Read JNJ sits 1% below its 52-week high after a 55% one-year run, with analyst consensus targets just 4% above current price. DARZALEX cleared $4 billion in Q2 and TREMFYA grew 71%, but STELARA's 60% collapse strips roughly 920 basis points from Innovative …

Projeções de Resultados: Johnson & Johnson (JNJ) — LPA e Crescimento de Receita

What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders

In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to …

Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The …

Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …

140-year-old Dividend King eyes bold update to unlock new growth

Most 140-year-old companies are coasting. Johnson & Johnson (JNJ) is restructuring. And that's the part of the J&J story that rarely gets enough attention. When people think of this company, they think of dividend checks and baby powder. A steady, predictable blue-chip that you …

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which …

ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers

Agreement supports ACCESS-affiliated ASCs in adopting the CARTO™ System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio …

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we …

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

Notícias das Ações da Johnson & Johnson (JNJ)

Johnson & Johnson (JNJB34)

The Market Is Flashing a Valuation Warning -- but History Shows These Stocks Can Handle the Turbulence

Key Points Johnson & Johnson has historically been a safe haven during turbulent times. Coca-Cola, like J&J, is a Dividend King with a record of resilience. Chevron is an energy giant with a huge AI tailwind.10 stocks we like better than Johnson & Johnson …

Johnson & Johnson (JNJ) Could Be 10% Overvalued Following Leadership Change

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (JNJ) is back in focus after longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced …

The $85 Billion Consolation Prize For JNJ Shareholders

Photo by Rigby40 on Pixabay The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them. Over the last five years, Johnson & Johnson (JNJ) sent $85 …

Johnson & Johnson (JNJ) Gets FDA Nod For OTTAVA As It Enters Surgical Robotics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) received FDA authorization for its OTTAVA robotic surgical system. The company is moving ahead with the commercial launch of …

This Surgical Robot Could Transform the Operating Room

After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race years earlier, or is the market already spoken for? View Comments

3 Dividend Stocks to Buy and Hold Forever

Collecting regular dividends is great for passive income or for unleashing the power of compounding through dividend reinvestment. That is, until a corporation decides to suspend its dividend program altogether. Fortunately, investors don't have to deal with that problem or, at least, can reduce …

Johnson & Johnson (JNJ) Stock Sees Modest Fair Value Lift After Analyst Target Increases

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Price targets on Johnson & Johnson have been moving higher, with bullish analysts now citing a range from about US$260 to US$305. This shift is closely linked …

Is Wall Street Bullish or Bearish on Johnson & Johnson Stock?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Let's …

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Abbott Laboratories (NYSE:ABT) and Johnson & Johnson (NYSE:JNJ) involves weighing steady growth against massive scale. Both healthcare giants offer stability, but which represents the superior investment for you in 2026? Abbott focuses on high-tech diagnostics and life-saving medical devices, while Johnson & …

Johnson & Johnson embarks on supply chain restructuring

This story was originally published on Supply Chain Dive. To receive daily news and insights, subscribe to our free daily Supply Chain Dive newsletter. Johnson & Johnson is undergoing a restructuring of its supply chain, primarily in its innovative medicine segment, according to a …

J&J Strikes $3.51 Bln Deal With Sail To Develop In-Vivo CAR-T Therapies For Immune Diseases

(RTTNews) - Johnson & Johnson (JNJ) on Thursday announced a strategic collaboration with Sail Biomedicines to develop in-vivo CAR-T cell therapies for immune-mediated diseases. The collaboration will leverage Sail's AI-driven Endless RNA (eRNA) platform and targeted nanoparticle platform along with other leading product engines, …

Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long …

Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T

Combines Sail's patented eRNA™ and targeted nanoparticle modality with Johnson & Johnson's world-class development, manufacturing, and commercialization capabilities to create scalable and potentially curative In Vivo CAR-T therapies for immune-mediated diseases Sail to receive initial payments of $785 million from Johnson & Johnson1, including …

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Advances differentiated immunology program with the potential to address significant unmet need in immune-mediated disease Novel in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body, enabling scalable treatments with durable, disease-modifying, and curative potential Strengthens Johnson & Johnson's leadership …

Explainer-Can J&J finally put the talc litigation behind it?

By Dietrich Knauth NEW YORK, July 29 (Reuters) - After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that could finally help …

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Key Points Eli Lilly currently displays stronger upward momentum in top-line growth, whereas Johnson & Johnson maintains a higher but flatter overall baseline. Over roughly the last eight quarters, the two companies experienced diverging patterns, with Johnson & Johnson staying mostly stable quarter over …

What Johnson & Johnson Stock Told You Before It Surged

Photo by kravaivan11 on Pixabay Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved. A Run That Matched Merck And More Than Tripled The S&P Over the year from late July 2025, Johnson …

Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation

Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation Proactive uses images sourced from Shutterstock Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, …